MyoKardia Priced, Nasdaq: MYOK

Clinical-stage biotech developing therapies for heritable cardiomyopathies.

Industry: Health Care

Latest Trade: $13.60 0.00 (0.0%)

First Day Return: +5.3%

Return from IPO: +36.0%

Industry: Health Care

We are a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Our initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. We have used our precision medicine platform to generate an initial pipeline of four therapeutic programs for the chronic treatment of the two most common forms of heritable cardiomyopathy—hypertrophic cardiomyopathy and dilated cardiomyopathy. We have discovered and advanced our lead product candidate, MYK-461, into Phase 1 clinical development. In our first Phase 1 clinical trial, we have demonstrated proof of mechanism, or the ability of MYK-461 to reduce cardiac muscle contraction, an important biomarker of disease. We intend to expand our approach to deliver treatments with disease-modifying potential for patients with other forms of genetically-driven heart failure.
more less
IPO News for MyoKardia
more
IPO Data
IPO File Date 09/28/2015
Offer Price $10.00
Price Range $15.00 - $17.00
Offer Shares (mm) 5.4
Deal Size ($mm) $54
IPO Data
IPO Date 10/28/2015
Offer Price $10.00
Price Range $15.00 - $17.00
Offer Shares (mm) 5.4
Deal Size ($mm) $54
Underwriters
more
Company Data
Headquarters South San Francisco, CA
Founded 2012
Employees 54
Website www.myokardia.com